Erem Cihangir
Department of Internal Medicine, Karadeniz Technical University, Trabzon, Turkey.
Endocrine. 2009 Aug;36(1):110-8. doi: 10.1007/s12020-009-9185-z. Epub 2009 Apr 15.
Various abnormalities of hemostasis, ranging from subclinical laboratory abnormalities to clinically significant disorders of hemostasis, and rarely major hemorrhage or thromboembolism, may occur in patients with thyroid diseases. The objective of this review is to discuss the relationships between thyroid dysfunction and hemostasis (primary hemostasis and coagulation/fibrinolytic system). According to the recent literature, most of the hemostatic abnormalities associated with thyroid dysfunction are the consequences of direct effects of thyroid hormones on the synthesis of various hemostatic parameters. Thyroid autoimmunity may also modify the processes of primary and secondary hemostasis. We have concluded that hyperthyroidism is generally associated with hypercoagulability and hypofibrinolysis, whereas the hemostatic profile in hypothyroidism depends on the severity of the disease. As few data are available on hemostasis in subclinical thyroid disease, further studies on this subject are needed.
甲状腺疾病患者可能会出现各种止血异常情况,从亚临床实验室异常到具有临床意义的止血障碍,很少出现大出血或血栓栓塞。本综述的目的是探讨甲状腺功能障碍与止血(初级止血和凝血/纤维蛋白溶解系统)之间的关系。根据最近的文献,大多数与甲状腺功能障碍相关的止血异常是甲状腺激素对各种止血参数合成直接作用的结果。甲状腺自身免疫也可能改变初级和次级止血过程。我们得出的结论是,甲状腺功能亢进通常与高凝状态和低纤维蛋白溶解有关,而甲状腺功能减退的止血情况则取决于疾病的严重程度。由于关于亚临床甲状腺疾病止血的资料很少,因此需要对此进行进一步研究。